The ATM filing signals a distressed capital raise for a pre-revenue biotech. Monitor for SEC effectiveness of the S-3 — once effective, the company can begin selling shares into the market, likely pressuring the stock. The prior Cantor facility's zero utilization suggests weak institutional demand; the switch to Jefferies may indicate more aggressive selling terms (3% fee). Short-term traders should watch for any announcement of first drawdown as a negative catalyst.
Price Chart
Executive Summary
Spero Therapeutics entered into a new at-the-market (ATM) equity offering agreement with Jefferies LLC for up to $100M in common stock, filed concurrently with a $300M universal shelf registration statement (S-3). The company also terminated its prior $75M Cantor Fitzgerald ATM facility, under which it had sold no shares in FY2025 or FY2024. The new ATM is 1.4x the company's $70M market cap, representing massive potential dilution for a clinical-stage biotech with no approved products or near-term revenue prospects, and the shelf registration was filed just 16 days after a 10-Q showing a $70M market cap, signaling a distressed capital raise to fund preclinical development of SP001.
Key Financial Metrics
Key Facts
- Entered into Open Market Sale Agreement with Jefferies LLC for up to $100M in common stock ATM offering.
- Filed universal shelf registration statement (S-3) for up to $300M in securities, not yet effective.
- Terminated prior Cantor Fitzgerald ATM facility ($75M capacity) effective August 28, 2026; no shares sold under that facility in FY2025 or FY2024.
- The $100M ATM is approximately 1.4x the company's $70M market cap, indicating severe dilution risk.
- Registration statement is not yet effective; no sales may occur until declared effective by the SEC.
Financial Impact
Potential dilution of up to ~143% of current market cap ($100M ATM vs $70M market cap) if fully utilized; no immediate cash inflow until S-3 declared effective.
Risk Factors
- Massive dilution risk if the full $100M ATM is utilized relative to a $70M market cap.
- No approved products or near-term revenue; capital raise funds preclinical SP001 development with uncertain clinical and regulatory outcomes.
- Historical performance on this ticker shows poor T+20 outcomes for bullish calls (avg -14% alpha), suggesting the market consistently prices in dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-374788 |
| Document: 0001193125-26-374788-index.html | 0001193125-26-374788 |
| Document: 0001193125-26-374788.txt | 0001193125-26-374788 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access